Skip to main content
Caplight Logo









Aurenar

Aurenar

Private
Saint Louis, MichiganHealthcare & Life Scienceshttps://www.aurenar.com/

Last Round

Seed

Jul 28, 2026

Total Funding Raised

$5.7M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Aurenar is a medical device company that develops a non-invasive, single-use neuromodulation platform designed to reduce life-threatening complications in intensive care unit patients.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

neuromodulationtransauricular vagus nerve stimulationtaVNSbioelectronic medicinemedical deviceneurotechnologyICU careintensive caredisposable medical deviceneurocritical carevagus nerve stimulationVNSclinical innovationFDA breakthrough device

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aurenar Comparables

Compare Aurenar with similar companies based on industry and business-model similarity.

Aurenar comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Evren Technologies
65%
Spark Biomedical Inc
62%
Surf Therapeutics
61%

Aurenar Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJul 28, 2026

Key People

Founding team and executive leadership

Anna Huguenard

Co-Founder, Chief Medical Officer

Founding Team

Eric Leuthardt

Chief Executive Officer and Founder

Founding Team

Ryan Kight

Chief Financial Officer

Executive Team

Aurenar Investors

Notable investors and investment history

Aurenar investors
InvestorRounds
Kaleida CapitalSeed
Solas BioVenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 1262% MoM, reaching 1.4K.

  • Aug 16, 2026

    Grew 30% QoQ from 10 to 13 employees.

Recent news

Latest coverage and updates

  • is_developingSep 21, 2026

    Aurenar is developing neuromodulation device aimed specifically at stroke recovery on Sep 21st '26.

  • receives_financingJul 28, 2026

    Aurenar received financing of $5.7M in Seed on Jul 28th '26.

  • is_developingJul 2, 2026

    Aurenar is developing V-Link.

  • recognized_asJul 1, 2026

    Aurenar recognized as FDA Breakthrough Device designation on Jul 1st '26.

Aurenar Filings

Explore SEC and related filing metadata, where available.

Aurenar filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Aurenar's valuation, stock price, and market status.

Is Aurenar a public or private company?

Aurenar is a private company.

What is the current stock price of Aurenar?

Aurenar is a private company with no public stock price. Caplight tracks Aurenar's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Aurenar worth (valuation)?

Valuation information for Aurenar is not publicly available.

Can I buy Aurenar stock?

Aurenar shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Aurenar's last funding round?

Aurenar's most recent funding round was Seed on July 28, 2026.

Who are the main investors in Aurenar?

Key investors in Aurenar include Solas BioVentures.

Will Aurenar IPO soon?

No public IPO plans have been announced for Aurenar.

How can I track Aurenar secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Aurenar's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSaint Louis, Michigan
Employee Range11
Year Founded2024
Last FundingJul 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?